For a child with altered mental status and blood glucose below 60 mg/dL, SNHD protocols call for weight-based intramuscular glucagon when IV access isn’t available. Learn how it raises blood sugar and why close monitoring and follow-up care still matter.

Multiple Choice

For an AMS pediatric patient with BgL <60 mg/dl when IV access is not available, which treatment is indicated?

When a pediatric patient is AMS with blood glucose below 60 mg/dL and IV access isn’t available, giving glucagon intramuscularly is the quickest and most reliable way to raise blood sugar. Glucagon acts by stimulating the liver to convert stored glycogen into glucose, so it can raise blood glucose without needing IV access. The dose is weight-based: 0.5 mg IM if the child weighs less than 20 kg, and 1 mg IM if they weigh more than 20 kg. This approach provides rapid correction and is specifically designed for scenarios where IV dextrose can’t be given right away. After giving glucagon, monitor the patient closely for a rise in glucose and improvement in mental status, and obtain IV access as soon as possible to continue treatment if needed. Epinephrine isn’t indicated for hypoglycemia, and dextrose solutions (D10) are given IV/IO; without access, they aren’t the preferred route here.

Pediatric Hypoglycemia: Why IM Glucagon Matters When IV Access Is Unavailable

A child with altered mental status and very low blood glucose needs prompt care. In the Southern Nevada Health District (SNHD) paramedic protocols, when a pediatric patient’s blood glucose is below 60 mg/dL and IV access is not available, intramuscular glucagon is the indicated treatment. The dose depends on the child’s weight: 0.5 mg IM for a child under 20 kg, or 1 mg IM for a child over 20 kg.

That route matters. Dextrose is commonly used to treat hypoglycemia, but it must be given through IV or IO access under this protocol. If access can’t be established right away, glucagon offers a way to act without waiting for a vein.

What low blood sugar can do to a child

Glucose is a key fuel for the brain. When blood sugar drops too low, the body may respond with sweating, shakiness, hunger, or a fast heartbeat. In a young child, those signs can be hard to spot or describe. If the drop continues, the child may become confused, unusually sleepy, unresponsive, or have a seizure.

Altered mental status (AMS) is a broad term, not a diagnosis on its own. A child may seem disoriented or difficult to wake for many reasons, so checking blood glucose helps identify a cause that can be treated quickly. A reading below 60 mg/dL, paired with AMS, calls for urgent attention within the relevant local protocol.

How glucagon raises blood sugar

Glucagon is a hormone that signals the liver to release glucose stored as glycogen. In simple terms, it asks the body to draw on a reserve fuel supply. Unlike IV dextrose, it doesn’t require a line into a vein, which is why an IM dose can be useful when access is unavailable.

There’s an important detail behind that mechanism: glucagon relies on the liver having stored glycogen available. Its effect may be limited if those stores are low, such as after prolonged fasting or in certain medical conditions. So it can be a useful bridge, but it doesn’t remove the need to reassess the patient and continue care as indicated.

Weight sets the pediatric dose

For the SNHD protocol described here, the IM dose is tied to the child’s weight:

  • Under 20 kg: 0.5 mg IM

  • Over 20 kg: 1 mg IM

Clear weight thresholds help reduce guesswork in a high-pressure setting. Clinicians still need to confirm the patient’s weight as accurately as circumstances allow and follow the current local protocol and medication guidance. If a child is exactly 20 kg, or the available guidance leaves any uncertainty, the treating team should consult the current protocol rather than assume which threshold applies.

What happens after the dose?

Giving glucagon is one step in care, not the whole plan. The team should continue to monitor blood glucose, level of consciousness, and the child’s overall condition. A change in the glucose reading is useful, but so is watching whether the child becomes more alert or shows other signs of improvement.

IV access should be obtained as soon as it is feasible when further treatment may be needed. If the child’s condition doesn’t improve, worsens, or the glucose remains low, clinicians need to reassess and follow the applicable protocol. Glucagon can also cause nausea or vomiting, so monitoring and attention to airway safety matter, especially when the patient is drowsy or unable to protect their airway.

The timing and amount of follow-up treatment depend on the patient’s response and the current protocol. A single medication dose should never be treated as proof that the underlying problem has been resolved.

Why not give dextrose by another route?

In this SNHD protocol, D10 is given IV or IO. Those routes allow dextrose to enter the circulation directly, but they require vascular access. D10 is not given IM or by mouth as a substitute route in this scenario.

That distinction is easy to miss: the medication and the route are part of the treatment together. A medication suitable for one route isn’t automatically safe or effective through another. When IV access is unavailable, the protocol points to IM glucagon rather than changing the route of dextrose.

Epinephrine has no role in treating low blood glucose. It is used for other emergency conditions, and giving it for hypoglycemia would not address the need to raise blood sugar.

A small dose, with a specific job

Pediatric hypoglycemia care is a good example of how emergency protocols connect a finding, a treatment, and a practical barrier. The low glucose reading points to a problem; the lack of IV access changes which treatment can be given immediately. In this situation, IM glucagon provides a route that doesn’t depend on establishing a line first.

The key details are straightforward: for a pediatric patient with AMS and blood glucose below 60 mg/dL, SNHD guidance calls for 0.5 mg IM below 20 kg and 1 mg IM above 20 kg when IV access is unavailable. Then the care team continues close monitoring, works to establish access when needed, and follows the current local protocol. That steady sequence—treat, reassess, and respond to the patient—helps keep care focused when every minute counts.